Mercury Pharmaceuticals

15

Sep 2026

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer. (WCLC).

READ MORE

15

Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

READ MORE

15

Sep 2026

Mobile LDCT lung cancer screening can reach vulnerable populations in resource-limited settings

Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

READ MORE

15

Sep 2026

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

READ MORE

15

Sep 2026

Investigational anti-CTLA-4 antibody improves survival in metastatic squamous NSCLC

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

READ MORE

15

Sep 2026

Study links processed foods to targeted domain-specific cognitive decline

An unhealthy Western-style diet was associated with a faster cognitive decline in people with a genetic risk of Alzheimer's disease, according to new research led by Murdoch University and Alzheimer's Research Australia.

READ MORE

15

Sep 2026

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

READ MORE

15

Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

READ MORE

15

Sep 2026

Study reveals characteristics and outcomes in NSCLC patients harboring class II and III BRAF alterations

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

READ MORE

15

Sep 2026

New IASLC grading system improves risk stratification in resected lung squamous cell carcinoma

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer.

READ MORE